• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Changing the future of clinical trials in Alzheimer’s disease

EPAD is pioneering a new approach to clinical trials of drugs designed to prevent Alzheimer’s disease.

Alzheimer’s disease is a progressive degenerative disease that results in a loss of brain cells. It is the most common form of dementia in the elderly. According to the World Alzheimer Report 2016, there were 46.8 million people worldwide living with dementia in 2015 and this number will reach 131.5 million in 2050.

While there is no cure for Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has approved two types of medications – cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) – to treat the cognitive symptoms of Alzheimer’s disease. However, despite intensive efforts over many years and significant global investment, no new drugs have been approved since 2003.

Prevention of Alzheimer’s dementia

There is now compelling evidence that Alzheimer’s disease takes hold in the brain decades before dementia symptoms appear, providing a window of opportunity for preventative intervention. As a result, today’s research increasingly focuses on this pre-symptomatic phase, with the aim of delaying or preventing the disease.

The European Prevention of Alzheimer’s Dementia (EPAD) consortium was an interdisciplinary research initiative aiming to improve the understanding of the early stages of Alzheimer’s disease and deliver new preventative treatments.

The largest ever public-private partnership in Alzheimer’s disease research, EPAD transcended disciplinary boundaries to combine knowledge and expertise from 39 European partner organisations across multiple sectors.

Early, targeted intervention

Research has established beyond doubt that Alzheimer’s dementia is a result of multiple disease processes. By the time symptoms appear, numerous pathologies have hampered brain function.

The hypothesis behind EPAD suggested that early, targeted intervention focused on the very first stages of disease will be more successful. This approach requires greater insight into the life of the brain than has ever been achieved before. Which disease processes are most relevant? What is the interaction between risk factors, disease and intervention? How do you find the right people to track over time? EPAD was set up to find the answers.

Tackling the challenges

EPAD faced a number of challenges, including the difficulty of identifying people who are likely to develop Alzheimer’s dementia, the poor understanding of the earliest stages of the disease, and a lack of flexibility in the way clinical trials are carried out.

To address these issues, we developed three core strategies which deliver benefits for intervention owners and research participants.

  1. The Register: EPAD has created the first single, pan-European register of over half a million people across the risk spectrum for dementia.
  2. The Cohort: From this register, research participants were invited to join an EPAD cohort of at-risk subjects, the Longitudinal Cohort Study, known as the LCS. This group underwent standardised tests and follow-up over several years.
  3. The Trial: EPAD was aiming to select participants to take part in streamlined proof-of-concept (PoC) trials of drugs designed to prevent Alzheimer’s dementia.

Watch the EPAD video for an overview of our approach.

Pioneering adaptive trials in Alzheimer’s dementia

The case for using adaptive trials as a methodology to research dementia is strong. With better data and improved decision-making, adaptive trials can increase the probability of success and decrease development time. EPAD is pioneering this approach in Alzheimer’s disease.

In traditional clinical trials, half of the participants receive the drug under investigation, and half receive a placebo. In adaptive clinical trials, several candidate drugs are simultaneously compared to each other and to a placebo, meaning that a greater proportion of patients benefit from a potentially active treatment. Furthermore, researchers can adapt the trial design in response to emerging results, new candidate drugs can be added, and those that prove ineffective can be dropped.

By setting up a trial-ready cohort of research participants, creating a pan-European network of trial sites, identifying ineffective medicines earlier in the development process and eliminating failures in more advanced (Phase III) trials, EPAD aimed to accelerate the development of effective therapies.

Please read more about EPAD’s platform for intervention owners.

Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.